While germline BRCA1 or BRCA2 mutations have, until recently, been the only validated indications for PARPi-based therapy in breast and ovarian cancer, it has become clear that they were not the sole causes of an HRD phenotype. Here, BRCA2 is linked to hypoparathyroidism-retardation-dysmorphism syndrome.